Discrepant results for standard loci across two centres.

<p>Discrepant results for standard loci across two centres.</p

Sizes of PCR fragments determined by the QiaXcel system.

<p>A–Standard loci. B–Hypervariable loci.</p

Combined agreement rates between QiaXcel and reference methods.

<p>Combined agreement rates between QiaXcel and reference methods.</p

Agreement of SLD testing in different laboratories in phase I and phase II of the “Baltic-Nordic TB-Laboratory Network” study.

<p>PAS, p-amino salicylic acid.</p

Discrepant results for hypervariable loci.

<p>Discrepant results for hypervariable loci.</p

Compilation of strains in round 1 of the WP3 of the TB PAN-NET” project.

<p>Compilation of strains in round 1 of the WP3 of the TB PAN-NET” project.</p

Interlaboratory agreement rates.

<p>Hypervariable loci shown in red colour. In cases where results from both laboratories were incorrect, these values were not included in discrepancies.</p

Methods applied in the different laboratories in both phases of SLD proficiency testing (“Baltic-Nordic TB-Laboratory Network” study).

*<p>some laboratories used more than one method.</p><p>PAS, p-amino salicylic acid.</p><p>LJ, Löwenstein Jensen; MIC, minimal inhibitory concentration.</p

Certificates issued for a succesful EQA round.

<p>Certificates issued for a succesful EQA round.</p

Agreement of SLD results between laboratories in the four rounds of quality control.

*<p>The majority of laboratories applied MGIT 960 DST, only one laboratory performed the proportion method on solid media, but the data are incomplete.</p>**<p>susc. = susceptible, res. = resistant; intermediate level strains were excluded from this analysis.</p>***<p>n.d. = not done.</p